Description from PRIDE: "To characterize transfer of molecules from target cells into CAR T cells via trogocytosis we cultured NALM-6 leukemia cell line expressing a CD19-mCherry fusion protein with CAR T cells. NALM6-CD19-mCherry were loaded with heavy amino acid and cocultured with CAR T cells for 1 hour. CAR T cells were next sorted into two fractions, mCherry-positive (TrogPos), and -negative...

Chimeric antigen receptor (CAR) therapy targeting CD19 yielded remarkable outcomes in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute myeloid leukemia (AML), we probed the AML surfaceome for over-expressed molecules with potentially tolerable systemic expression. We integrated large transcriptomics and proteomics data sets from malignant and normal tissues, and...

Summary from GEO: "Single cell gene expression profile of WT and SUV39H1-edited CAR T cells at pre-infusion (Day 0), day 9 and day 16 post infusion in tumor (NALM6) bearing NSG mice" Overall design from GEO: "Unedited and SUV39H1-edited human CAR T cells were sorted from bone marrow (at day 9 and 16) from tumor bearing NSG mice. Pre-infusion single cell gene expression profiling of unedited and...

Summary from GEO: "Comparing genome accessibility profiles (ATACseq) of WT and SUV39H1-edited CAR T cells" Overall design from GEO: "Unedited and SUV39H1-edited human CAR T cells were sorted from bone marrow (at day 50) of NSG mice that had undergone multiple rounds of NALM6 rechallenge"

Summary from GEO: "Comparing transcriptional profiles (RNAseq) of WT and SUV39H1-edited CAR T cells" Overall design from GEO: "Unedited and SUV39H1-edited human CAR T cells were sorted from bone marrow (at day 50) of NSG mice that had undergone multiple rounds of NALM6 rechallenge"

Summary from GEO: "The choice of costimulatory domain in CAR design dictates the kinetics of in vivo anti-tumor responses, affecting potency, quality and durability. We show that 1928z results in more vigorous effector functions, whereas 19BBz design compensates for their lesser cytotoxic potency by steadily building up their numbers. Therapeutic function can be further improved by combining CD28...